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The epidemiology of tuberculosis (TB) in the United 
States is changing as the incidence of disease becomes 
more concentrated in foreign-born persons. Mycobacterium 
bovis appears to be contributing substantially to the TB in-
cidence in some binational communities with ties to Mexico. 
We conducted a retrospective analysis of TB case surveil-
lance data from the San Diego, California, region from 1994 
through 2005 to estimate incidence trends, identify correlates 
of M. bovis disease, and evaluate risk factors for deaths dur-
ing treatment. M. bovis accounted for 45% (62/138) of all cul-
ture-positive TB cases in children (<15 years of age) and 6% 
(203/3,153) of adult cases. M. bovis incidence increased sig-
niﬁ  cantly (p = 0.002) while M. tuberculosis incidence declined 
(p<0.001). Almost all M. bovis cases from 2001 through 2005 
were in persons of Hispanic ethnicity. Persons with M. bovis 
were 2.55× (p = 0.01) as likely to die during treatment than 
those with M. tuberculosis. 
T
he pattern of tuberculosis (TB) in the United States 
is changing as the incidence of TB disease becomes 
more concentrated in foreign-born persons. Of the annual 
total US TB cases, >54% are now concentrated in persons 
born outside of the United States (1); in communities with 
high immigration, the proportion can exceed 70% (2). TB 
prevention and treatment strategies, particularly those in 
communities on the border with Mexico, will need to be 
adapted to accommodate the changing epidemiology of 
TB (3).
San Diego, California, together with its sister city 
Tijuana-Tecate, Mexico, is the largest binational metro-
politan region in the United States, accounting for 34% of 
the southern border population (4). In San Diego County, 
the Hispanic population has grown from 20% to 29% in 
the past 15 years (5). Of the total annual TB cases in San 
Diego, >70% occurred among foreign-born persons, of 
whom nearly half originated from Mexico (2). A review of 
culture-positive TB cases in San Diego County in the late 
1990s indicated that 6.6% of all adult TB cases and 39% of 
all pediatric (<15 years of age) TB cases from this region 
were not caused by Mycobacterium tuberculosis, the most 
common TB pathogen in the United States, but were in-
stead caused by M. bovis, a pathogen more often associated 
with TB in cattle (6). This ﬁ  nding represented the high-
est reported proportional incidence of TB from M. bovis 
among industrialized countries (7).
M. bovis is a pathogen in the complex of bacteria that 
includes M. tuberculosis, which causes TB in humans and 
animals. TB from M. bovis has been generally considered 
rare in the United States after its successful eradication 
from cattle in the mid-1900s (8), but wider use of labora-
tory tools for species-level diagnosis of TB pathogens has 
started to shed light on an unexpected regional presence 
of M. bovis in communities with large Hispanic popula-
tions. While M. bovis TB has been most often documented 
in Hispanic communities with close proximity to Mexico 
(6,9), a recent review of M. bovis cases in New York City 
indicates that the problem is not limited to US regions that 
border Mexico (10).
The clinical and pathologic characteristics of M. bovis 
TB is indistinguishable from M. tuberculosis TB in most 
cases, but there are relevant considerations for prevention 
and treatment strategies in communities where M. bovis 
contributes to TB incidence. First, M. bovis is thought to 
be spread to humans primarily through consumption of raw 
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dairy products and inhalation of infectious droplets from 
cattle (11,12), with only minimal human-to-human trans-
mission (13). Second, M. bovis is almost universally resis-
tant to the key antituberculous drug pyrazinamide (PZA), 
which necessitates a 9-month treatment duration instead 
of the standard 6-month, short-course therapy, which is 
possible with PZA in the treatment regime. Third, higher 
mortality rates during treatment may be associated with M. 
bovis (14).
Multidrug-resistant (MDR) strains of M. bovis (15–
17), the high proportional incidence of M. bovis (9,18) in 
pediatric TB cases, and frequent HIV co-infection (19) are 
important additional considerations in developing effective 
treatment and prevention strategies for M. bovis. To docu-
ment the trends and the effect of M. bovis on TB epidemi-
ology, we examined TB case surveillance data from 1994 
through 2005 in San Diego County and identiﬁ  ed risk fac-
tors related to M. bovis disease and deaths during treatment 
in the last 5 years.
Methods
Data Sources
This study used routine TB surveillance data from 
1994 through 2005. The study protocol was approved 
by the Institutional Review Boards of San Diego State 
University and the University of California, San Diego. 
Demographic and clinical data were obtained from the 
Tuberculosis Information Management System (TIMS) 
database maintained by the San Diego County TB Con-
trol Program. Since the early 1990s, a TB isolate has been 
submitted to the county public health laboratory for every 
reported TB case. All TB isolates from patient specimens 
were initially identiﬁ  ed as M. tuberculosis complex on 
the basis of the AccuProbe hybridization protection as-
say (GenProbe, San Diego, CA, USA). Specimens were 
further identiﬁ  ed as either M. bovis or M. tuberculosis 
on the basis of culture morphologic ﬁ  ndings, the results 
of the niacin strip test, the nitrate reduction test, and the 
specimens’ susceptibility to PZA (20). Furthermore, all 
isolates identiﬁ  ed as M. bovis from 2004 and 2005 were 
conﬁ  rmed to have spoligotypes consistent with M. bovis 
(21). Population data for San Diego County were obtained 
from San Diego Association of Governments’ estimates 
based on census and calculated data.
Study Design
We conducted a retrospective trend analysis of all 
culture-positive TB cases in the San Diego County TIMS 
database from 1994 through 2005 that were conﬁ  rmed as 
either M. bovis or M. tuberculosis. We also conducted a 
detailed retrospective analysis of demographic and clinical 
variables associated with M. bovis case-patients and deaths 
during treatment from 2001 through 2005.
Demographic variables from the TIMS database used 
in the correlates and mortality analyses included sex, age, 
ethnicity, and country of birth. Clinical variables includ-
ed: previous history of TB disease, presence or absence 
of pulmonary disease, presence or absence of multisite 
disease, presence or absence of acid-fast bacilli (AFB) in 
sputum smear, presence or absence of pulmonary lesions 
by chest radiograph, presence or absence of MDR TB, 
and HIV status.
Analysis
Trends
Trends in TB incidence were evaluated by using Pois-
son regression with time in years as the predictor variable, 
case number as the dependent variable, and population size 
as an additional exposure variable. Trend lines for M. bovis 
and M. tuberculosis were based on incidence predicted by 
Poisson regression ﬁ  tted to the data. Trends in proportional 
incidence of M. bovis cases (relative to all TB cases) were 
assessed with a χ2 test for trend.
Correlates of M. bovis Disease
Demographic and clinical variables shown previously 
to be associated with TB diagnoses (6) were compared be-
tween M. bovis and M. tuberculosis. Variables signiﬁ  cant at 
the 5% level by χ2 test in univariate analyses were entered 
into a multiple logistic regression model. The ﬁ  nal model 
was derived by using the likelihood ratio method (22).
Analysis of Mortality Rates during Treatment 
All deaths that occurred from the time that a TB case 
was reported until treatment was completed were docu-
mented with death certiﬁ  cates and recorded in TB case 
ﬁ  les. For the purposes of this study, causes of death in M. 
bovis and M. tuberculosis case ﬁ  les were transcribed from 
death certiﬁ  cates or California state death records and col-
lated into 7 major causes of death based on the most com-
mon causes.
We investigated the apparently higher mortality rates 
during treatment among M. bovis cases relative to M. tu-
berculosis cases (14) by using a multiple logistic regression 
analysis with M. bovis as the exposure variable; death be-
fore treatment was completed as the outcome variable; and 
demographic and clinical variables as potential covariates. 
Univariate differences between causes of death in M. bovis 
and M. tuberculosis cases were analyzed with the Fisher 
exact test.
910  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 6, June 2008M. bovis TB in Binational Communities
Results
Trends
Analysis of TB trends from 1994 through 2005 in-
cluded 3,291 culture-positive cases of TB and excluded 
806 cases (20%) that were based only on national and local 
clinical case deﬁ  nitions. Among all culture-positive cases, 
M. bovis was isolated in 8% (265/3,291) and M. tubercu-
losis in 92% (3,026/3,291). M. bovis accounted for 45% 
(62/138) of all culture-positive TB cases in children <15 
years of age and 6% (203/3,153) of cases in adults (>15 
years of age). No cases of M. bovis occurred in children 
<12 months of age.
During the period under study, incident cases of M. 
bovis TB increased linearly (p = 0.002; Figure) at 4.1% per 
year from 17 cases (0.65/100,000 population) to 28 cases 
(0.93/100,000) per year. TB cases from M. tuberculosis de-
clined in a nonlinear fashion (p<0.001) from 317 cases per 
year (12.1/100,000 population) to 221 cases (7.33/100,000). 
The annual proportion of TB cases attributed to M. bovis 
increased from 5% of all culture-positive cases in 1994 to 
11% in 2005 (p<0.001, Table 1). The proportion of TB cas-
es with culture-positive results remained relatively stable at 
≈81% of annual reported TB cases.
Correlates of M. bovis Disease
Of the 1,324 culture-positive TB cases reported 
from 2001 through 2005, M. bovis accounted for 10% 
(132/1,324), comprising 54% (29/54) of cases among 
children <15 years of age and 8% (103/1,270) among 
adults (>15 years of age). Of the M. bovis TB cases, 
>96% were found in persons of Hispanic ethnicity, and 
60% were among those of known Mexican origin. Uni-
variate analysis indicated that sex, previous TB episode, 
and sputum AFB smear results were not signiﬁ  cantly dif-
ferent between M. bovis and M. tuberculosis case-patients 
(Table 2). No MDR TB cases were identiﬁ  ed among the 
M. bovis cases, whereas 1.5% of the M. tuberculosis cases 
had initial isolates that were MDR (deﬁ  ned as resistant to 
at least both isoniazid and rifampin). All of the M. bovis 
isolates were resistant to PZA, whereas 0.8% of the M. 
tuberculosis cases were PZA resistant. Of the 1,316 TB 
cases included in the multiple logistic regression model, 
factors associated with M. bovis disease included Hispan-
ic ethnicity, multisite disease, being 5–14 years of age, 
and having extrapulmonary disease with a normal chest 
radiograph. HIV co-infection was not signiﬁ  cantly more 
associated with M. bovis disease compared with M. tuber-
culosis (p = 0.08; Table 3).
Analysis of Mortality Rates during Treatment
Of 1,324 culture-positive TB case-patients, 1,119 
were evaluated in the analysis of mortality rates during 
treatment. Fifteen percent (205/1,324) were excluded be-
cause of missing data on case survival, including patients 
who were lost to follow-up or moved during treatment. Of 
the 1,119 cases, 110 (19 M. bovis and 91 M. tuberculo-
sis) patients died during TB treatment (n = 81) or before 
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Figure. Trends in incidence of culture-positive tuberculosis (TB) 
cases from Mycobacterium bovis and M. tuberculosis in San Diego 
County, California, 1994–2005.
Table 1. Proportional contribution of Mycobacterium bovis and M. tuberculosis to total culture-positive TB cases, San Diego County, 
California, 1994–2005* 
Year Total TB cases Total no. (%) culture-positive TB cases† No. (%)‡ M. bovis cases No. (%)‡ M. tuberculosis cases
1994 420 334 (80) 17 (5) 317 (95)
1995 438 308 (70) 18 (6) 290 (94)
1996 384 302 (79) 11 (4) 291 (96)
1997 332 266 (80) 17 (6) 249 (94)
1998 342 270 (79) 31 (11) 239 (89)
1999 299 225 (75) 19 (8) 206 (92)
2000 295 262 (89) 20 (8) 242 (92)
2001 330 274 (83) 23 (8) 251 (92)
2002 317 272 (86) 25 (9) 247 (91)
2003 315 258 (82) 29 (11) 229 (89)
2004 320 271 (85) 27 (10) 244 (90)
2005 305 249 (82) 28 (11) 221 (89)
*TB, tuberculosis. 
†Excludes 11 case-patients who had an isolate of M. tuberculosis complex resistant to pyrazinamide, but did not have species-level identification. Percent 
given is of all TB cases. 
‡Percent given is of total culture-positive TB case-patients. RESEARCH
treatment was begun (n = 29). M. bovis patients who died 
during treatment were treated for a similar duration (mean 
61 days, standard deviation [SD] 93.9) as M. tuberculosis 
patients (mean 60 days, SD 101.3).
No deaths during treatment were recorded in the pedi-
atric M. bovis TB case-patients; 1 pediatric death was re-
corded among the M. tuberculosis TB treatment cases. In 
a multivariate analysis (n = 1,119), M. bovis patients were 
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Table 2. Univariate comparison of Mycobacterium bovis cases relative to M. tuberculosis cases, San Diego County, California, 2001–
2005*
Characteristic
No. (%)†M. bovis cases,
n = 132
No. (%)† M. tuberculosis cases, 
n = 1,192 Univariate p value
Sex 0.15
  M 75 (56.8)  754 (63.2) 
 F 57 (43.2)  438 (36.7) 
Age group, y <0.001
  0–4 15 (11.4)  10 (0.8) 
 5–14 14 (10.6)  15 (1.3) 
 15–24 21 (15.9)  156 (13.1) 
 25–44 46 (34.8)  409 (34.3) 
 45–64 20 (15.2)  356 (29.9) 
 >64 16 (12.1)  246 (20.6) 
Race/ethnicity <0.001‡
  Hispanic 128 (96.9)  529 (44.3) 
 White 3 (2.27)  151 (12.6) 
 Asian 1 (0.75)  420 (35.2) 
 Black 0 86 (7.2)
 Other 06 ( 1 . 0 )
Country of birth <0.001
  Mexico 79 (59.8)  382 (32.0) 
 United  States 53 (40.2)  302 (25.3) 
 Philippines 0 248 (20.8) 
 Other 0 260 (21.8) 
Previous TB 0.52
  Yes 5 (3.8)  60 (5.0) 
 No 127 (96.2)  1128 (94.6) 
 Unknown§ 04 ( 0 . 3 )
Sputum AFB smear result 0.16
  Positive 40 (30.3)  590 (49.4) 
 Negative 43 (32.5)  461 (38.6) 
 Not  done§ 49 (37.1)  141 (11.8) 
Disease site <0.001
  Pulmonary 71 (53.7)  1031 (86.4) 
 Extrapulmonary 61 (46.2)  161 (13.5) 
Clinical manifestations <0.001
  Single site disease 84 (63.6)  1036 (86.9) 
 Multisite  disease 48 (36.4)  156 (13.1) 
Chest radiograph lesions <0.001
  No lesions 55 (41.7)  123 (10.3) 
  Pulmonary lesions consistent with TB 75 (56.8)  1063 (89.2) 
 Unknown§ 2 (1.5)  6 (0.5) 
HIV status <0.001
  Negative 48 (36.4)  611 (51.3) 
 Positive 33 (25.0)  107 (9.0) 
 Unknown 51 (38.6)  474 (39.8) 
Treatment outcome 0.02
  Died before treatment completed 19 (14.3)  91 (7.6) 
  Alive at end of treatment 102 (77.2)  913 (76.5) 
 Unknown 11 (8.3)  188 (15.7) 
*TB, tuberculosis; AFB, acid-fast bacillus. 
†Percentages do not always add up to 100% due to rounding. 
‡Fisher exact p value. 
§Not included in Ȥ
2 calculation. M. bovis TB in Binational Communities
2.55× (p = 0.01) as likely to die before treatment comple-
tion than M. tuberculosis patients, after differences in age, 
race and ethnicity, country of birth, chest radiograph abnor-
malities, multisite disease, and HIV status were accounted 
for (Table 4). Univariate analyses of the causes of death in 
M. bovis and M. tuberculosis cases showed no signiﬁ  cant 
differences (p>0.05) except for the category of “other non-
infectious disease,” which was overrepresented in the M. 
tuberculosis group (Table 5). 
Discussion
From 1994 through 2005, incidence of M. bovis TB 
cases in San Diego County increased in absolute number, 
as a proportion of total TB cases, and relative to the popu-
lation. In contrast, TB incidence caused by M. tuberculosis 
declined during the same period. M. bovis cases were con-
centrated in persons of Hispanic descent, especially those 
of Mexican origin, and among those <15 years of age, in 
whom M. bovis accounted for 45% of the culture-positive 
cases. Deaths during treatment were largely conﬁ  ned to 
adults and were twice as high in M. bovis TB case-patients 
when compared with M. tuberculosis patients.
Our ﬁ  ndings indicate that the incidence of TB caused 
by M. bovis in southern California is substantially higher 
than the national rate of 1.5% estimated from TB surveil-
lance data (23) but is similar to the proportional incidence 
(13%) among Mexican-born case-patients in New York, 
New York. It was previously hypothesized that TB attrib-
uted to M. bovis in San Diego is most likely being driven by 
recent infections in children and largely reactivated latent 
infections in adults, secondary to HIV co-infection (6). Our 
ﬁ  ndings conﬁ  rm the continued high incidence of M. bovis 
in children >12 months of age, but the role of HIV co-in-
fection in M. bovis case-patients relative to M. tuberculosis 
cases is less clear.
Almost half of the culture-positive pediatric TB cases 
in this binational region of >3 million persons were caused 
by M. bovis, which has clinical implications. Since M. bo-
vis is intrinsically resistant to PZA, a critical component 
of the standard 6-month, short-course treatment for M. 
tuberculosis, M. bovis treatment is usually extended to 9 
months of isoniazid and rifampin (14). In southern Cali-
fornia, and perhaps other Hispanic communities with close 
ties to Mexico, empiric extended TB treatment for children 
without culture-positive disease, particularly those with a 
history of consuming unpasteurized dairy products, should 
be considered.
Although one quarter of the M. bovis TB case-patients 
were co-infected with HIV, HIV was not signiﬁ  cantly more 
associated with M. bovis TB compared with M. tuberculosis 
in our study or in the previous M. bovis study in this com-
munity (6). Conﬁ  dence in this ﬁ  nding is somewhat limited 
because 40% of the TB case-patients did not have their HIV 
status reported. However, because most of the case-patients 
with an unknown HIV status were <15 or >55 years of age, 
the age groups at lowest risk for HIV, these missing data 
likely did not mask an association if one exists.
HIV co-infection plays a role in the epidemiology of 
adult M. bovis TB, but likely the growing Hispanic popula-
tion with close ties to Mexico, and not HIV, is the major 
driving force behind the increasing number of M. bovis cas-
es we observed. Given the long latency of this disease, the 
unclear role of airborne transmission in M. bovis TB (13), 
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Table 3. Odds ratios from final logistic regression model of 
variables correlated with TB from Mycobacterium bovis versus  
M. tuberculosis, San Diego County, California, 2001–2005* 
M. bovis  vs. M. tuberculosis
(n = 130 vs. n = 1,186) 
Risk factors  OR (95% CI)  p value 
Age group, y (ref >65 y)  0.002
 0–4  2.43  (0.81–7.28)  0.11
 5–14  4.38  (1.38–13.9)  0.01
 15–24  1.06  (0.45–2.49)  0.90
 25–44  0.68  (0.31–1.45)  0.32
 45–64  0.50  (0.21–1.15)  0.10
Race/ethnicity (ref = white)  <0.001
 Hispanic  7.97  (2.36–26.93) <0.001 
 Asian  0.08  (0.01–0.76)  0.03
 Black  0 0.99
 Other  0 0.99
Extrapulmonary disease  4.51 (2.36–8.62)  <0.001
Normal chest radiograph results  3.16 (1.63–6.11)  <0.001
Multisite disease  4.31 (2.54–7.3)  <0.001
HIV status† (ref = negative)  0.13
 Positive  1.75  (0.93–3.29)  0.08
 Unknown  0.87  (0.48–1.58)  0.65
*n = 1,316. TB, tuberculosis; OR, odds ratio; CI, confidence interval; ref, 
referent. 
†Variable not significant in multivariate analysis. 
Table 4. Factors associated with death before completion of TB 
treatment in TB patients, San Diego County, California, 2001–
2005*
Risk factor  OR (95% CI)  p value 
Mycobacterium bovis disease  2.55 (1.27–5.11)  0.01
HIV infection (ref = negative)  <0.001
 Positive  4.50  (2.19–9.24)  <0.001
 Unknown  2.09  (1.19–3.67)  0.01
Age group, y (ref = 0–4 y)  <0.001
 5–14  Not  defined  1.00
 15–24  0.79  (0.06–9.88)  0.86
 25–44  1.54  (0.17–13.78)  0.70
 45–64  4.75  (0.55–41.12)  0.16
>65 17.19 (2.04–145.01) 0.01
Country of birth (ref = United States)  <0.001
 Mexico  0.52  (0.30–0.90)  0.02
 Philippines  0.52  (0.28–0.97)  0.04
 Other  0.25  (0.12–0.53)  <0.001
Chest radiograph lesions  2.21 (0.97–5.05)  0.06
Multisite disease  1.86 (1.10–3.15)  0.02
*n = 1,119. TB, tuberculosis; OR, odds ratio; CI, confidence interval; ref, 
referent. RESEARCH
and the ﬂ  uid population dynamics of the San Diego region, 
however, the true population at risk and what might be be-
hind the trends observed are difﬁ  cult to describe. The rela-
tive contributions of reactivated latent M. bovis infection 
compared with recent infection could not be discerned in 
our study, but prudent prevention strategies would include 
a focus on eliminating consumption of unpasteurized dairy 
products in both adults and children in the United States 
and Mexico.
Our study conﬁ  rms earlier preliminary ﬁ  ndings (14) 
that M. bovis case-patients appear to be more than twice 
as likely to die before TB treatment completion compared 
with M. tuberculosis patients, despite being treated for 
the same mean number of days. The association of higher 
mortality rates during M. bovis treatment persisted after 
HIV, multisite disease, age, and ethnicity were accounted 
for. Causes of death related to noninfectious disease, such 
as malignancy and noninfectious gastrointestinal patholo-
gies, were underrepresented in the M. bovis cases (0 vs. 
25%), but, overall, the M. bovis and M. tuberculosis cases 
were not signiﬁ  cantly different with regard to all causes 
of death.
In mouse models, evidence indicates that certain strains 
of M. bovis are more virulent than M. tuberculosis strains 
(24), but those ﬁ  ndings are not generally supported in the 
literature on human M. bovis TB (7). Although our mortal-
ity analysis partially controlled for extent of disease, it did 
not include information on coexisting conditions, stage of 
HIV disease, diagnostic delays, and prior access to medical 
care. Therefore, M. bovis deaths might be accounted for by 
other factors, such as health disparities or treatment differ-
ences, which warrant further investigation.
Public health measures to control TB are currently 
focused on interrupting person-to-person transmission by 
promptly identifying and treating infectious patients and 
ensuring that they do not expose new contacts until treat-
ment has rendered them noninfectious. Based on our data, 
these strategies, which have proven to be effective at reduc-
ing M. tuberculosis cases in San Diego and most regions of 
the United States, appear to be less effective in controlling 
M. bovis, suggesting that human-to-human transmission 
of M. bovis is less likely an important mode of transmis-
sion in this community. The consumption of contaminated 
dairy products has been proposed to be the primary source 
of human TB from M. bovis (25). This hypothesis is sup-
ported by the ﬁ  ndings of an investigation of M. bovis cases 
in New York that indicated the likely source of infection 
was unpasteurized cheese from Mexico (10). Additionally, 
San Diego pediatric M. bovis cases occur only after the age 
of weaning, when children are typically ﬁ  rst exposed to 
dairy products (6), and M. bovis was also recently cultured 
from unpasteurized cheese seized at the San Diego–Mexico 
border (26,27).
Because of the widespread adoption of pasteurization 
of all commercially available dairy products in the United 
States, as well as the aggressive US state agricultural health 
programs designed to keep dairy cattle free from M. bovis 
disease, the threat of M. bovis in US dairy products was 
largely eliminated in the mid-20th century (8). The San 
Diego–Tijuana binational region, however, shares one of 
the busiest border crossings in the United States with Baja, 
Mexico (28), where M. bovis is prevalent in cattle and con-
sumption of unpasteurized dairy products is a common cul-
tural practice (29–32). Mexican dairy products, including 
the popular queso fresco (soft, unpasteurized cheese), may 
be brought into the United States for personal use and are 
sometimes distributed illegally (27). Given our ﬁ  nding that 
>90% of M. bovis cases in San Diego occurred in Hispan-
ics, most of whom were born in Mexico, consumption of 
unpasteurized dairy products from Mexico is likely a major 
risk factor for M. bovis TB in San Diego. Collaboration 
with Mexico on prevention strategies, from education to 
regulation of the production of unpasteurized dairy prod-
ucts, and elimination of M. bovis from dairy cattle will be 
required in the long term to ensure that this mode of trans-
mission is eliminated.
Limitations
A growing awareness of M. bovis as a cause of TB in 
San Diego since 1980 could have introduced a sampling 
bias into our trend estimates, but this possible bias is un-
likely to have had a considerable effect in the years 1994 
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Table 5. Primary causes of death before treatment completion in Mycobacterium bovis and M. tuberculosis TB case-patients (n = 110), 
San Diego County, California, 2001–2005* 
Cause of death No. (%) Mycobacterium bovis case-patients No. (%) M. tuberculosis case-patients  p value†
Pulmonary TB 2 (11)  20 (22)  0.42
Extrapulmonary TB 3 (16)  8 (9)  0.58
Pulmonary NOS 08 ( 9 ) 0 . 4 1
HIV related 6 (32)  12 (13)  0.11
Cardiovascular 7(37) 18 (20) 0.19
Infectious (not TB) 1(5) 2 (2) 0.84
Other noninfectious   disease 0 23 (25) 0.01
Total 19 91
*TB, tuberculosis; NOS, not otherwise specified. 
†Fisher exact test. M. bovis TB in Binational Communities
through 2005 as reported here. All suspected TB cases in 
San Diego County are reportable to the health department, 
and the county laboratory has consistently conducted test-
ing to distinguish all M. tuberculosis complex isolates as 
either M. bovis or M. tuberculosis since 1994. The propor-
tion of TB cases based only on clinical diagnosis and not 
species level culture has remained relatively level, at ≈20% 
of all reported TB cases. Increased efforts to obtain speci-
mens for culture in pediatric TB cases in the years under 
study did not appear to change the proportion of culture-
positive cases during the study period.
The cohort of TB case-patients who were not culture-
positive and thus excluded from this analysis was signiﬁ  -
cantly different from the study group. The <15-year age 
group (36% vs. 4%, respectively) and Hispanic ethnicity 
(57% vs. 45%) were both overrepresented in the excluded 
cases. Given that these are the groups most likely to have 
M. bovis TB, the total incidence of M. bovis, particularly in 
children, may be underestimated in our study.
Conclusions
San Diego, California, while unique in many respects 
because of its close proximity to Mexico, is possibly rep-
resentative of other communities in the United States with 
large and growing Hispanic populations with ties to Mexi-
co. The considerable and growing incidence of TB from M. 
bovis, especially in children, and the observed number of 
deaths during treatment in these cases is of serious concern. 
It raises the question of the importance of incorporating 
routine species-level identiﬁ  cation into US TB surveillance 
as the national TB incidence shifts to persons born outside 
the United States. This surveillance will be greatly facili-
tated by the national genotyping project implemented by 
the US Centers for Disease Control and Prevention in 2004 
(33), and its use will be particularly important for commu-
nities with strong ties to Mexico.
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